Physician profile
Daniel J Weber
NPI 1215166814
$48,692.24
in general payments reported to CMS, 2019-2025
14 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $6,831 · 2021: $17K · 2022: $22K · 2023: $764 · 2024: $829 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $45,816.70 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,050.20 | 2019-2024 | Briviact |
| Jazz Pharmaceuticals INC. | $669.98 | 2022-2025 | |
| Greenwich Biosciences, INC. | $277.89 | 2021 | |
| Neurelis, INC. | $272.88 | 2021-2025 | Valtoco |
| Boston Scientific Corporation | $142.73 | 2025 | General - Dbs |
| Sunovion Pharmaceuticals INC. | $118.13 | 2019-2022 | |
| Genzyme Corporation | $111.30 | 2022 | |
| Neuropace, INC. | $63.49 | 2023 | |
| Eisai INC. | $45.29 | 2022 | |
| Medtronic USA, INC. | $41.54 | 2019 | |
| Geistlich Pharma, North America, INC. | $29.30 | 2023 | Bio-Materials |
| Livanova USA, INC. | $27.89 | 2022 | |
| Medtronic, INC. | $24.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.